Tag Archives: mpn

NCCN Guidelines for MPN Reflect New Drugs, Focus on Clinical Trials

Posted on by

October 11, 2024

Author(s): Interview by Mary Caffrey

Understanding of myeloproliferative neoplasms (MPNs), a group of blood cancers that occur when a person’s bone marrow makes too many blood cells, has increased since discovery of the JAK2 mutation in 2005.1 Still, the first set of National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPNs, which include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET), did not appear until 2017, and through 2022 there were few updates.

But since then, the NCCN Guidelines for MPNs have had multiple updates per year, with the latest in August 2024,2 a sign of increased activity in the field. In an interview with The American Journal of Managed Care® (AJMC®), Aaron Gerds, MD, MS, who chairs the panel handling the MPN updates, confirms that the more frequent updates reflect new approvals and more options for patients.

Aaron Gerds, MD, MS | Image credit: Cleveland Clinic

“We are regularly looking at the published literature and updates in the field in order to make sure that these guidelines are very nimble, and that they are adjusted to reflect current practice,” said Gerds, who is associate professor of medicine and deputy director for clinical research at the Cleveland Clinic Taussig Cancer Institute. Some guidelines might be updated every 5 to 10 years; but if there’s nothing new, “there’s not a lot of sense in updating things in a large way.”

Conversely, updates often occur when new therapies are approved or become available, Gerds said, as was the case in September 2023 when momelotinib (Ojjaara), the fourth Janus kinase (JAK) inhibitor, became available for the treatment of intermediate or high-risk MF, including primary MF or secondary MF, and post-PV, and post-ET in adults with anemia.3

The most recent update puts a major focus on clinical trials; in many circumstances, they are listed as the preferred option over FDA-approved therapies; in the AJMC interview, Gerds explains how a pair of phase 3 trials involving ruxolitinib combinations will produce results very soon.

Read more

Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping

Posted on by

The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients

| Source: Precipio, Inc.

NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines released in August of this year (Version 2.2024—August 8, 2024).

This is the only quantitative PCR-based panel of its kind on the market that distinguishes between CALR Type 1 and Type 2 alongside the other genes relevant to the molecular evaluation of MPN.

“As science and discovery constantly evolve the diagnostic world, Precipio is committed to maintaining its competitive advantage and being at the forefront of our industry,” said Ilan Danieli, Precipio CEO. “Our customers and their patients will continue to benefit from access to cutting-edge technologies combined with the highest clinical value, enhancing patient care.”

Clinical Significance of CALR Subtyping in MPN Management
The inclusion of CALR mutation subtyping is a direct response to the evolving landscape of MPN patient care where understanding the specific type of CALR mutation can influence treatment strategies and outcomes.

Read more

JAK Inhibitors Diversify the Field of Myelofibrosis Symptom and Spleen Management

Posted on by

October 8, 2024

Author(s): Ashling Wahner

Fact checked by: Courtney Flaherty

The wealth of JAK inhibitors available for managing myelofibrosis invites the development of increasingly personalized treatment plans based on individual patient needs and disease characteristics, according to Idoroenyi Amanam, MD.

“We’ve come a long way since ruxolitinib [Jakafi] was FDA approved,” Amanam said in an interview with OncLive®. “We have a better understanding of which patients benefit from JAK inhibitors, and we are clearer on the shortcomings of JAK inhibitors.”

In the interview, Amanam discussed how JAK inhibitors measure up against other available therapies in myelofibrosis; patient characteristics that are most likely to indicate benefit with JAK inhibitors; and which of these agents he is likely to choose based on patients’ platelet counts, symptom burden, and treatment history.

For instance, Amanam highlighted the importance of pacritinib (Vonjo) in the myelofibrosis treatment paradigm. Pacritinib was approved by the FDA in 2022 for the treatment of select adult patients with intermediate- or high-risk myelofibrosis with thrombocytopenia based on findings from the phase 3 PERSIST-2 trial (NCT02055781), in which 29% patients who received the agent achieved a spleen volume reduction (SVR) of at least 35%. Among patients who received best available therapy, the SVR rate was 3%.1

He also explained the role of momelotinib (Ojjaara) for patients with anemia. Momelotinib was FDA-approved in 2023 for the treatment of adult patients with intermediate- or high-risk myelofibrosis and anemia based on data from the phase 3 MOMENTUM trial (NCT04173494).2 In MOMENTUM, 25% of patients who received momelotinib (n = 32/130) experienced a Myelofibrosis Symptom Assessment Form 4.0 total symptom score reduction of at least 50% vs 9% of those who received danazol (Danocrine; n = 6/65), translating to a treatment difference of 16% (95% CI, 6%-26%; P < .0095).3

Amanam is an assistant professor in the Division of Leukemia in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California.

Read more

Study Findings Suggest Use of Fedratinib as Treatment in the Second Line for Myelofibrosis

Posted on by

October 3, 2024

Author(s): Alexandra Gerlach, Associate Editor

Fedratinib (Inrebic; Bristol Myers Squibb) demonstrates safety and efficacy as a second line Janus kinase inhibitor (JAKi) option to reduce spleen size after ruxolitinib (Jakafi; Incyte Corp) failure or intolerance in patients with myelofibrosis (MF), according to results from the FREEDOM2 trial (NCT03952039). The study compared treatment with fedratinib and the best available therapy (BAT) in intermediate- or high-risk primary MF.1

The results support the potential of fedratinib as a JAK-2 inhibitor in the second line as a therapeutic option for patients intolerant or resistance to ruxolitinib.

Image Credit: © NeuroGraphix Studio – stock.adobe.com

MF is an uncommon, fatal myeloproliferative neoplasm characterized by the overproduction hematopoietic stem cells, leading to increasingly reduced red blood cell production. As a result, many patients with MF, approximately 40%, have anemia at diagnosis, of which an estimated 25% are RBC transfusion dependent (TD). In most cases, patients will develop chronic anemia and TD as the disease progresses.2,3

Ruxolitinib is a JAKi approved by the FDA in 2011 and indicated for the treatment of patients with intermediate or high-risk myelofibrosis, including primary MF (PMF), post-polycythemia vera MF (post-PV MF) and post-essential thrombocythemia MF (post-ET MF). Despite its success for some patients, the response rate is less than 50% and survival rates after ruxolitinib discontinuation are poor. Many patients develop ruxolitinib intolerance and become relapsed or refractory.4,5

Fedratinib is an orally available, small molecule inhibitor of JAK-2, which is often mutated in patients with MF. It was approved in 2019 by the FDA as a therapeutic option for intermediate- or high-risk primary or secondary MF and has demonstrated clinically meaningful benefits for patients. In multiple preregistration trials, fedratinib resulted in reduction spleen size and improvement in symptoms in 40% to 50% of patients, including those who were resistant or intolerant to ruxolitinib.6

Read more

Novel Biomarker Could Predict MF Progression

Posted on by
Özge Özkaya, MSc, PhD

C-mannosyl tryptophan could be a novel biomarker to predict the progression of myelofibrosis (MF) in thrombocytosis of myeloproliferative neoplasms, according to a new study published in the journal Scientific Reports.

“Present studies evaluating C-mannosylation using this novel assay for progression to overt MF in [essential thrombocythemia] may provide promising future directions,” the researchers wrote.

To assess C-mannosyl tryptophan in human hematological diseases, the team, led by Shinobu Tamura, PhD, from the Wakayama Medical University in Japan, quantified the levels of the amino acid in the serum of 94 healthy people using hydrophilic interaction liquid chromatography.

They found that the platelet count was positively correlated with the levels of C-mannosyl tryptophan in the serum.

They then assessed the clinical significance of C-mannosyl tryptophan in thrombocytosis of myeloproliferative neoplasms, including essential thrombocythemia, by measuring the levels of the amino acid in the serum of 34 patients with thrombocytosis of myeloproliferative neoplasms and compared this to the levels in the serum of 52 patients with other hematological disorders.

They found that serum levels of C-mannosyl tryptophan were significantly higher in patients with thrombocytosis. Moreover, the amino acid’s serum levels were inversely correlated with anemia, which was related to MF.

Finally, the researchers analyzed the bone marrow biopsy samples of 18 patients with essential thrombocythemia and measured the levels of C-mannosyl tryptophan in their serum at the same time. They found that 12 patients with bone marrow fibrosis had significantly higher levels of C-mannosyl tryptophan compared to the 6 patients without bone marrow fibrosis.

Read more

New Insights Emerge on Treatment Outcomes for Accelerated or Blast-Phase Myeloproliferative Neoplasms

Posted on by
Tori Rodriguez, MA, LPC, AHC

In recent years, several new therapies approved by the US Food and Drug Administration for the treatment of acute myeloid leukemia (AML) have been used in the management of accelerated or blast-phase myeloproliferative neoplasms (MPN-AP/BP). However, due to a dearth of prospective data on the efficacy of these therapies in patients with MPN-AP/BP, there remains a lack of consensus regarding their use in this population.1

In a retrospective, multicenter cohort study published in Blood Advances, researchers aimed to address this gap by investigating outcomes among 202 patients with MPN-AP/BP who were diagnosed and treated in the current era of myeloid therapies.1

Study Findings

The results demonstrated a median overall survival (OS) of 0.86 years, with no significant differences observed by first-line treatment type. The most common frontline strategies were intensive chemotherapy, DNA methyltransferase inhibitor (DNMTi)-based regimens, and DNMTi plus venetoclax–based regimens.1

An analysis of 65 patients who went on to receive allogeneic hematopoietic stem cell transplant (allo-HSCT) revealed a median OS of 2.30 years from the time of transplant.

In an interview with Hematology Advisor, study co-author Evan Chen, MD, a medical oncologist at Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School in Boston, Massachusetts, described 2 main takeaways from the findings: “First, outcomes of patients with MPN-AP/BP remain poor despite intensive chemotherapy and more recently developed, less-intensive venetoclax-based combinations. Second, a bone marrow transplant remains necessary for the possibility of long-term survival in the current treatment era for these patients.”

Despite the poor outcomes observed in this patient population, the present study found that “only 14% of patients were enrolled in clinical trials, and the criteria for assessing response in these patients is heterogeneous,” noted American Society of Hematology (ASH) media expert Ruben A. Mesa, MD, president and executive director of Atrium Health Wake Forest Baptist Comprehensive Cancer Center in Winston-Salem, North Carolina.

Read more

Education on MPN Symptoms, Treatments Leads to Greater Involvement in Care

Posted on by

October 3, 2024

Author(s): Darlene Dobkowski, MA

Fact checked by: Alex Biese

Learning more about the different symptoms and treatment goals of myeloproliferative neoplasms (MPNs) can help patients be more involved in management decisions throughout the disease trajectory, an expert said.

“It’s not just the doctor and the nurses; it’s the person who has the disease [that] is the main person, so their involvement is very important,” said Dr. Swati Goel at the recent CURE® Educated Patient® Updates in MPNs at Montefiore Medical Center in the Bronx, New York.

Goel is the Leader of the Myeloproliferative Disorder Clinic, assistant director of the hematology-oncology fellowship program and associate professor in the department of oncology and medicine at Montefiore Einstein in New York, New York.

Throughout the event, Goel discussed that there are three types of MPNs: polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis.

Read more

High Rates of Polycythemia Vera Remission Seen With Ruxolitinib Plus Peg-IFN

Posted on by
Andrea S. Blevins Primeau, PhD, MBA

Final results from the phase 2 COMBI II trial demonstrated high rates of remission of newly-diagnosed polycythemia vera (PV) after treatment with ruxolitinib plus pegylated-interferon-α2a (peg-IFN), according to a report published in Blood Advances.

The COMBI I trial previously demonstrated efficacy and safety of the combination of ruxolitinib with peg-IFN among patients who were refractory or intolerant to peg-IFN monotherapy and/or hydroxyurea.

“This study supports the previously described theory that combination therapy with ruxolitinib and peg-IFN may be one of the most promising treatment options in patients with myeloproliferative neoplasms,” the researchers wrote in their report.

In the investigator-initiated, single-center, phase 2 study, researchers treated 25 adult patients with newly-diagnosed PV with ruxolitinib and peg-IFN. All patients underwent pretreatment phlebotomies and patients who were high-risk, aged 60 or older, or who had a prior thrombosis also received hydroxyurea.

The primary endpoint was safety and secondary endpoints included complete remission (CR), peripheral blood count remission (PBCR), and bone marrow histologic remission (BMHR).

The median age of the patients was 70 years and 56% were male. The median number of phlebotomies from diagnosis to study entry was 3. There were 76% of patients who were considered high-risk, 20% had a prior thrombosis, and 12% had splenomegaly. The median hemoglobin was 13.8 g/dL and the median hematocrit was 0.44 IQR. The median variant allele fraction (VAF) of JAK2 V617F at baseline was 54 IQR.

Remission was achieved by 52% of patients by 12 months, with 12% of patients having achieved a CR. At 24 months, the overall remission rate was 56% and the CR rate remained at 12%.

Read more

Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what’s the current standard of care?

Posted on by
Mahesh Swaminathana, Akhil Jain, Sungchul Daniel Choi & Naveen Pemmaraju
Received 10 Jun 2024, Accepted 23 Sep 2024, Published online: 03 Oct 2024

ABSTRACT

Introduction

JAK inhibitors (JAKi) have changed the treatment paradigm of myelofibrosis (MF). Currently, 4 JAKis are approved in the US as monotherapy (mono) to treat patients with MF. JAKis are also being studied in combination (combo) with novel agents. Herein, we review some of the key studies that evaluated JAKi as mono and combo in MF.

Areas covered

We performed a Pubmed search for ‘JAK inhibitors’ and ‘myelofibrosis’ from 1/2010 to 12/2023. For mono, we included only the unique phase II/III studies of the approved JAKi. Selective studies that evaluated JAKi in combo with the novel agents were also included.

Expert opinion

JAKis aim to provide clinical benefit to patients via spleen size reduction and MPN symptom improvement. In order to potentially increase clinical benefit for patients with MF, several novel agents are being partnered with ruxolitinib (RUX) with the ongoing hypothesis to augment greater measures of MF disease modification. The novel agents are either ‘added-on’ to RUX or as a combo in JAKi naïve patients. Also, the mutant-targeting era of therapies is now beginning with novel CALR-mutated, novel JAK2 V617F mutation-specific and type II JAK2i in the initial stages of drug development, representing a new approach to treatment.

Read more

Choosing the Right JAK Inhibitor for Effective Myelofibrosis Treatment

Posted on by

By Jordyn Sava
Fact checked by Sabrina Serani

With 4 JAK inhibitors approved in the US and additional agents in development, it is an exciting time for the field of myeloproliferative neoplasms (MPNs). Now, experts face the challenge of determining which treatment is best for each patient.

Ruxolitinib (Jakafi), an established JAK inhibitor, was first approved by the FDA in 2011,1 showing clear survival benefits. This was followed by the FDA approvals of fedratinib (Inrebic) in 2019,2 pacritinib (Vonjo) in 2022,3 and momelotinib (Ojjaara) in 2023.4

“Each [JAK inhibitor has] their place depending on the patient’s blood counts and other clinical factors,” explained Prithviraj Bose, MD, in an interview with Targeted OncologyTM.

With multiple JAK inhibitors available to choose from, a tailored approach ensures that each patient’s specific disease characteristics and comorbidities are considered to maximize efficacy and minimize toxicity during treatment.

In the interview, Bose, professor in the Department of Leukemia at MD Anderson Cancer Center, discussed the multiple JAK inhibitors available for the treatment of patients with MPNs.

Read more